Cancer Research Annual Meeting 2010  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 45, 4785-4790, October 1, 1985]
© 1985 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noguchi, S.
Right arrow Articles by Matsumoto, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noguchi, S.
Right arrow Articles by Matsumoto, K.

Mechanism of Estrogen Enhancement in the Growth of Androgen-dependent Shionogi Carcinoma 1151

Shinzaburo Noguchi, Daishiro Takatsuka, Yukihiko Kitamura, Nobuyuki Terada, Naomi Uchida, Kenji Yamaguchi, Bunzo Sato and Keishi Matsumoto2

Departments of Pathology [S. N., D. T., K. M.] and Internal Medicine [B. S.] and Institute for Cancer Research [Y. K., N. T.], Osaka University Medical School, Kita-ku, Osaka 530, Japan; Shionogi Research Laboratories [N. U.], Fukushima-ku, Osaka 553, Japan; and Kobe Women's College [K. Y.], Chuo-ku, Kobe 650, Japan

The mechanism of estrogen enhancement in the growth of androgen-dependent Shionogi carcinoma 115 (SC115) maintained in castrated DS mice by low doses of androgen (10 µg of testosterone propionate or 4 µg of 5{alpha}-dihydrotestosterone/mouse/day) is reported. Although the low androgen treatment slightly but significantly (P < 0.05) stimulated tumor growth, concomitant estrogen (4 µg of 17ß-estradiol/mouse/day) significantly (P < 0.01) enhanced the tumor growth. The high growth rate, histological type (medullary carcinoma), androgen dependency, and high androgen receptor content of the tumor grown during estrogen plus low androgen treatment did not differ significantly from those of the original SC115 tumor grown in normal males or in castrated mice treated with high doses of androgen. On the other hand, the treatment with low doses of androgen alone induced the development of slowly growing spindle-shaped cells from the medullary SC115 cells. The spindle-shaped cells containing low levels of androgen receptor were shown to be androgen independent and were also induced from the SC115 cells in nontreated castrated mice. These findings demonstrated that low doses of androgen and estrogen synergize to maintain and increase the growth of SC115 cells, whereas low doses of androgen alone fail to maintain the SC115 cells.

1 Supported in part by a grant-in-aid for Cancer Research from the Ministry of Education, Science, and Culture and the Ministry of Health and Welfare.

2 To whom requests for reprints should be addressed.

Received 12/ 3/84. Revised 7/ 1/85. Accepted 7/ 3/85.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1985 by the American Association for Cancer Research.